News & Events

Chesapeake PERL is pleased to announce these recent corporate updates:


US Army call C-PERL a Success Story

January 2010, US Army (USAMRAA) Contract: Large Quantity Production of Enzymes of Interest

October 2009, US Army SBIR Grant Year II: Commercialization Pilot Program (CPP), Improved Protein Manufacturing in Insect Expression System - Develop HIV-1 Envelope Proteins as HIV Vaccine Antigen 

June 2009, Department of Energy SBIR Grant Phase II: Identification, Production and Characterization of Novel Lignase Proteins from Termite for Depolymerization of Lignocellulose (http://www.science.doe.gov/sbir/awards_abstracts/sbirsttr/cycle26/phase2/p2_award.htm)

May 2009, US Army DTRA Contract: Development and Production of Recombinant Human Paraoxonase 1 (HuPON1)

October 2008, Research Products are now available (more).  Also, to better serve our clients and customers you can reach us Toll Free at 1-888-60C-PERL (1-888-602-7375).

September 2008, BEI Resources Contract: Production of Variola Recombinant Proteins at C-PERL


Social Media

Become a fan, find or follow us at these great networks!
 
 
 
Events

2012 

April 2-4, 2012 IS Biotech, Rosslyn, VA. Dr. Buchman to present: Recombinant Human Paraoxonase 1 Expressed by Baculovirus Infection of Whole Insect Larvae: A Potential Therapeutic for Lipidemia and Stroke. Click here to review abstract.

2010

October 7-8, 2010 NIH Research Festival. Booth #1008

May 5-6, 2010, 2010 Biomedical Research Equipment and Supplies Exhibit at NCI-Frederick/Ft. Detrick, Booth #335A http://www.gtpmgt.com/attendees.php?id=1

May 12-13, 2010, 2010 NIH Spring Research Festival Exhibit Booth #416A http://www.gtpmgt.com/attendees.php?id=6

June 6-11, 2010, VACCINE TECHNOLOGY III, Nuevo Vallarta, Nayarit, Mexico, Poster presentation An Alternative Platform for Rapid, High Yield, Low Cost Production of Vaccine Antigens http://www.engconf.org/10aa.html


June 6-11, 2010, Vaccine Technology III, Nuevo Vallarta, Nayarit, Mexico. Poster presentation An Alternative Platform for Rapid, High Yield, Low Cost Production of Vaccine Antigens http://www.engconf.org/10aa.html